California AB-1990 would raise ingredient, record-keeping, and advertising rules for compounded GLP-1 medications. What it could mean for you.
A plain-language look at what peer-reviewed studies actually show about hair loss, thyroid and pancreatic cancer, and fatigue on GLP-1 medications.
A plain-language look at what the research shows about GLP-1 weight loss, divorce rates, and how relationships really change on the medication.
What are peptides and how do they differ from GLP-1 medications? A plain-language guide to BPC-157, CJC-1295, ipamorelin, and more.
New 2026 genetics research explains why GLP-1s work better for some people than others, plus what to do if your response feels slower than expected.
A calm, plain-language explainer on SNAC, the absorption helper in oral semaglutide pills, and what the new 2026 study actually found.
A plain-language side-by-side of Foundayo and the Wegovy pill. Dosing, weight loss, side effects, and cost compared for 2026.
A plain-language refresh on the difference between a GLP-1 medication and a peptide, updated for 2026 and the arrival of non-peptide GLP-1 pills.
FDA statements, tariffs, and lawsuits have compounded GLP-1 patients' worries. Here is what is changing, what is not, and what it means for your price
Your GLP-1 dose is in mg. Syringes shows units. Learn why they differ, how concentration changes your count, and what to do when your vial changes.
The FDA approved Foundayo (orforglipron) on April 1, 2026. Here is what the new once-daily GLP-1 pill actually changes for patients.
Wegovy HD (7.2 mg) is now FDA-approved with 20.7% average weight loss. Learn about results, effects, availability, and how it compares to Zepbound.
